Lower Limb Amputations: Invokana / Farxiga / Jardiance / Invokamet / Xigduo / Glyxambi / Synjardy / Qtern / Steglatro / Steglujan / Segluromet
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
The diabetes Type-2 drugs Invokana, Farxiga, and Jardiance, as well as Invokamet, Xigduo, Glyxambi, Synjardy, Qtern, Steglatro, Steglujan, and Segluromet have been associated with these serious side effects:
- Toe(s) Amputations
- Foot Amputations
- Leg Amputations
- Fournier’s Gangrene (Necrotizing Fasciitis of the Perineum)
All of these diabetes drugs are Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors, a new class of diabetes medicines.
We are currently investigating possible drug injury lawsuits against the responsible pharmaceutical companies for diabetes patients who have developed the medical conditions listed above.
We encourage you to submit a Drug Injury Law Case Review – it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible drug injury case. Either way, you will get Mr. Lamb’s impressions — not an intake person, a paralegal, nor some other lawyer — about your case based on his many years of experience.
Most Recent Article About These Drugs
A “Black-Box Warning” about the increased risk of lower limb amputations was added to the drug labels for Invokana and Invokamet in July 2017.
Since that time there has been a mix of opinions expressed in the medical literature about whether or not lower limb amputations are a side effect of all diabetes medicines in the sodium-glucose co-transporter-2 (SGLT2) inhibitors class of drugs — which includes Farxiga and Jardiance — or limited only to Invokana and Invokamet.
To read more of this article, click below:
This ongoing discussion, or controversy, is the subject of this December 5, 2018 piece, “The SGLT2 Inhibitor-Amputation Link”, by medical news reporter Judy George, from which we get the following excerpt:
There are several reasons why questions about SGLT2 inhibitors and amputations aren’t resolved, said Michael Fischer, MD, MS, of Harvard Medical School.
“One challenge in assessing this risk is that amputations are relatively rare events,” Fischer explained.
Although the Johns Hopkins analysis [which showed that starting treatment with SGLT2 inhibitors was tied to a significantly greater risk of amputations compared with new use of sulfonylureas, metformin, and thiazolidinediones (HR 2.12)] included a large number of patients treated with SGLT2 inhibitors, there were only 18 total amputations observed in that study, he noted….
For Fischer, the results from the randomized controlled CANVAS trial remain “the most reliable evidence that we have so far on the risk of amputation, and should be factored into clinicians’ prescribing decisions.”
It seems fair to say that the SGLT2 inhibitors drug class amputations side effect issue remains open to debate.
Over the past couple of years we have been contacted by patients who had lower limb amputations while using Farxiga, Jardiance, and other diabetes medicines in the SGLT2 inhibitors drug class other than Invokana and Invokamet. We are evaluating those amputation cases and possible drug injury lawsuits against the responsible pharmaceutical companies.[Read article in full at original source]
Earlier articles by attorney Tom Lamb on the Side Effects Blog:
- Farxiga And Jardiance Have Two-Time Increased Risk For Amputations
- Amputations Are Diabetes Drugs Side Effects For SGLT2 Inhibitors Class
- Lower Limbs Amputations Are SGLT-2 Inhibitors Drug-Class Side Effects
- Fournier’s Gangrene: Side Effect For Invokana, Farxiga, And Jardiance
- Increased Risks Of Lower-Limb Amputations For Farxiga And Jardiance
- Invokana, Jardiance, And Farxiga Have Increased Risks Of Amputations
- Jardiance – Lower Limb Amputations Drug Safety Issue Remains Uncertain
- New Analysis Finds An Increased Risk Of Bladder Cancer For Jardiance
- Invokana – Amputations: No Explanation Yet As Regards “How” And “Why”
- “Dear Doctor” Letter About Invokana And Amputations Was Sent In Canada
- FDA Reports Show Extent And Nature of Invokana-Amputation Side Effect
- Invokana Gets “Black-Box Warning” For Risk Of Leg And Foot Amputations
- Jardiance, Invokana, And Farxiga Double Risk Of Diabetic Ketoacidosis
- Farxiga MDL Includes Diabetic Ketoacidosis And Kidney Damage Lawsuits
- Federal Court Invokana MDL In New Jersey With Judge Brian Martinotti
- New Federal Court Multidistrict Litigation (MDL) For Farxiga Lawsuits
- Invokana Has New Warning About Risk Of Lower Limb Amputation In Canada
List of SGLT2 Inhibitors
|Drug Name||Active Ingredient(s)||Drug Manufacturer||FDA Approval Date|
|Invokamet||canagliflozin / metformin||Janssen Pharmaceuticals||2014|
|Invokamet XR||canagliflozin / metformin extended-release||Janssen Pharmaceuticals||2016|
|Xigduo XR||dapagliflozin / metformin extended-release||AstraZeneca Pharmaceuticals||2014|
|Qtern||dapagliflozin / saxagliptin||AstraZeneca Pharmaceuticals||2017|
|Jardiance||empagliflozin||Boehringer Ingelheim Pharmaceuticals||2014|
|Glyxambi||empagliflozin / linagliptin||Boehringer Ingelheim Pharmaceuticals||2015|
|Synjardy||empagliflozin / metformin hydrochloride||Boehringer Ingelheim Pharmaceuticals / Eli Lilly and Company||2015|
|Synjardy XR||empagliflozin / metformin hydrochloride extended-release||Boehringer Ingelheim Pharmaceuticals / Eli Lilly and Company||2016|
|Steglatro||ertugliflozin||Merck Sharp & Dohme Corp. / Pfizer Inc.||2017|
|Steglujan||ertugliflozin / sitagliptin||Merck Sharp & Dohme Corp. / Pfizer Inc.||2017|
|Segluromet||ertugliflozin / metformin hydrochloride||Merck Sharp & Dohme Corp. / Pfizer Inc.||2017|
All content by attorney Tom Lamb